Skip to main content

SMARCA4-deficient Malignant Tumors clinical trials at UCSF

1 research study open to eligible people

SMARCA4-deficient malignant tumors are cancers caused by changes in the SMARCA4 gene. UCSF is studying how two immunotherapy drugs, nivolumab and ipilimumab, work together to treat these cancers in children and young adults. This research aims to find new treatment options.

Showing trials for

Our lead scientists for SMARCA4-deficient Malignant Tumors research studies include .

Last updated: